Monday, 1 June 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 01 June 2026
News

June PBS listings unpacked

Posted 1 June 2026 PM

A new fixed duration option for blood cancers plus a new adrenaline autoinjector are among additions to the PBS this month, with changes also made to the PBS listing for Amgen’s Blincyto.

AstraZeneca’s BTK inhibitor Calquence is now also reimbursed for use in combination with venetoclax (also known as AbbVie’s Venclexta) as a fixed duration regimen for the treatment of patients with CLL or SLL that have not already been treated with drug treatment.

To see the whole article, please login

Popular

Industry pay stalls, feet get itchy
Senior exec leaves pharma
Why Drs are losing trust in pharma
New Parkinson's drug approved
Latest Jobs
Pharma in Focus  Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home